Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
PT320, a sustained-release GLP-1 receptor agonist, ameliorates L-DOPA-induced dyskinesia in a mouse model of Parkinsons disease
We detail how alterations in gut microbiota metabolites, following dysbiosis disrupt blood-brain barrier (BBB) integrity and exacerbate neuroinflammation, ultimately leading to the neuropathology of SZ
Against this backdrop, maintaining regular meal structure, basic self-monitoring, and simple cognitive strategies such as stimulus control may help patients navigate rising appetite and routine changes during tapering and the early post-treatment phase
US$ 24.76
US$ 22.47
US$ 22.08
US$ 28.42
US$ 26.06
US$ 25.87
US$ 26.72
US$ 24.78
US$ 20.95
US$ 23.41
US$ 25.54
US$ 23.76
